Viking Therapeutics
Develops clinical-stage therapies for obesity, metabolic and endocrine disorders.
$32.24
After-hours close+0.10 (+0.31%)
At close$32.14(−5.08%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 69.73%81.35M sharesInsiders 2.96%3.45M sharesOther 27.31%31.85M shares
Shares outstanding 116.65M · Float 113.39M · 97.2% free float
Institutions13F, as of Jun 30, 2026
469 holders · 81.35M shares · 76 new positions · 224 increased · 131 reduced · 55 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 6.34M | 5.43% | +311.0K | Aug 13, 2026 |
| BlackRock, Inc. | 6.19M | 5.31% | −690.6K | Aug 7, 2026 |
| State Street Corp | 5.61M | 4.81% | +1.21M | Aug 7, 2026 |
| Vanguard Capital Management LLC | 5.05M | 4.33% | +41.2K | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 4.48M | 3.84% | +20.0K | Aug 13, 2026 |
| Two Sigma Investments, LP | 3.94M | 3.38% | −494.7K | Aug 14, 2026 |
| Morgan Stanley | 3.49M | 2.99% | +472.1K | Aug 13, 2026 |
| Ameriprise Financial Inc | 2.16M | 1.85% | +477.3K | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 5.10% | 5.77M | 13G | Nov 5, 2025 ↗ |
| Vanguard Capital Management | 5.08% | 5.88M | 13G | Apr 30, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Brian Lian | director, officer: President & CEO | 2.57M | 2.21% | Jul 29, 2026 |
| Marianna Mancini | officer: Chief Operating Officer | 422.8K | 0.36% | Jul 29, 2026 |
| Greg Zante | officer: Chief Financial Officer | 212.2K | 0.18% | Jul 29, 2026 |
| Matthew W. Foehr | director | 132.0K | 0.11% | Jan 5, 2026 |
| Lawson Macartney | director | 51.1K | 0.04% | Jan 5, 2026 |
| Charles A. Jr Rowland | director | 33.2K | 0.03% | Jan 5, 2026 |
| J. Matthew Singleton | director | 12.7K | 0.01% | Jan 5, 2026 |
| Dorothy Elizabeth Kelly-Gemmell | director | 6.3K | 0.01% | Aug 7, 2026 |
| Neil William Aubuchon | officer: Chief Commercial Officer | 4.5K | 0.00% | Mar 10, 2026 |
| Sarah Kathryn Rouan | director | 4.4K | 0.00% | Jan 5, 2026 |
1 ten-percent owner holds 5.82M shares by Form 4, outside the officers-and-directors figure above · 5 people have not refiled in the last 18 months (1.00M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 29, 2026 | Marianna Manciniofficer: Chief Operating Officer | Sale | 18,217 | $33.47 | 422,760 |
| Jul 29, 2026 | Greg Zanteofficer: Chief Financial Officer | Sale | 21,217 | $33.47 | 212,204 |
| Jul 29, 2026 | Brian Liandirector, officer: President & CEO | Sale | 148,517 | $33.32 | 2,572,441 |
| Mar 10, 2026 | Neil William Aubuchonofficer: Chief Commercial Officer | Purchase | 4,475 | $33.50 | 4,475 |
| Jan 2, 2026 | Matthew W. Foehrdirector | Sale | 16,000 | $35.11 | 132,036 |
| Jan 5, 2026 | Brian Liandirector, officer: President & CEO | Sale · 4 lots | 233,409 | $32.96 | 2,499,291 |
| Jan 5, 2026 | Marianna Manciniofficer: Chief Operating Officer | Sale · 4 lots | 57,661 | $32.98 | 409,190 |
| Jan 5, 2026 | Greg Zanteofficer: Chief Financial Officer | Sale · 4 lots | 57,661 | $32.90 | 189,891 |
| Oct 28, 2025 | Greg Zanteofficer: Chief Financial Officer | Sale | 6,185 | $35.00 | 173,592 |
| Oct 28, 2025 | Brian Liandirector, officer: President & CEO | Sale | 38,989 | $35.01 | 2,419,109 |
CongressHouse and Senate disclosures
Not reported.